Clinical trials: HFpEF - Heart Failure with Preserved Ejection Fraction
Heart Failure, Heart Failure With Preserved Ejection Fraction
HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets
HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and…
- Trial name
- NCT05873634
- Where
- 6 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Heart Failure With Preserved Ejection Fraction (HFpEF)
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days…
- Trial name
- PARAGLIDE-HF (NCT03988634)
- Testing
- sacubitril/valsartan, valsartan
- Where
- 97 sites in United States, Canada
- Volunteers
- 467 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure With Reduced Ejection Fraction
Consistently Assess Signs and Symptom of Heart Failure
Heart failure (HF) is a major public health problem. The New York Heart Association (NYHA) Functional Classification by a HF provider helps to guide their decisions in patient treatment.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Trial name
- CLASS-HF (NCT05833581)
- Testing
- New York Heart Association Classification Guide
- Where
- 3 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Board of Trustees of Illinois State University
Heart Failure
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
- Trial name
- NCT03611153
- Testing
- AZD4831 Oral Myeloperoxidase Inhibitor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Heart Failure With Normal Ejection Fraction, Obesity
Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients
The investigators hypothesize that a dietary intervention aimed at increasing unsaturated fatty acids (UFA) consumption is feasible and has the potential to improve cardiorespiratory fitness, metabolic flexibility and glucose…
- Trial name
- NCT03310099
- Testing
- Increasing daily unsaturated fatty acid consumption
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Virginia Commonwealth University
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF
US Benchmarking Clinical Study
The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin…
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy
- Trial name
- EMS-CT-1 (NCT07215715)
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- eMyosound SAS
Pulmonary Hypertension Due to Left Heart Disease, Heart Failure With Preserved Ejection Fraction
Training in HFpEF-PH
Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved…
- Trial name
- TRAIN HFpEF (NCT05464238)
- Testing
- Exercise rehabilitation, Standard treatment
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 90 people
- Sponsor
- Heidelberg University
Diastolic Heart Failure
A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]
The investigators hypothesized that udenafil, a newly developed phosphodiesterase type 5 inhibitor, would improve symptom, exercise capacity and hemodynamic status in patients with heart failure with preserved ejection fraction…
- Trial name
- NCT01599117
- Testing
- Udenafil (Zydena)
- Where
- 2 sites in South Korea
- Volunteers
- 52 people
- Sponsor
- Seoul National University Hospital
Heart Failure With Preserved Ejection Fraction, Hypomagnesemia
Intracellular Magnesium and Heart Failure
Low magnesium levels are surprisingly common in those with a heart condition known as HFpEF, where the heart pumps well but is too rigid to fill properly with blood.
- Trial name
- NCT06353750
- Testing
- Magnesium supplement
- Where
- United Kingdom
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Heart Failure, Physical Exercise
Comparison of the Effect of Two Types of Physical Exercises in Patients With Heart Failure With Preserved Ejection Fraction
Background: Heart failure (HF) is a chronic disease with a very important and increasingly severe social and health impact with a prevalence of 6.8% in Spain.
- Conditions
- Heart Failure, Physical Exercise, Exercise Capacity, Diastolic Function
- Trial name
- ExIC-FEp (NCT05726474)
- Testing
- Combined exercise, High interval training
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- University of Castilla-La Mancha
Heart Failure With Preserved Ejection Fraction
Prediction of the Development of Heart Failure With Preserved Ejection Fraction
The ultimate goal of the PREDICT-HFpEF study is to identify and unravel predictors for the development of heart failure with preserved ejection fraction (HFpEF) in a cohort at increased cardiovascular risk.
- Trial name
- PREDICT-HFpEF (NCT04894968)
- Testing
- Assessment of the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016
- Where
- Germany
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Heart Center Leipzig - University Hospital
Heart Failure With Preserved Ejection Fraction (HFPEF)
Role of Cardiopulmonary Exercise Testing in People With Heart Failure With Preserved Ejection Fraction
Heart failure affects 1-2% of the adult population. Up to half of these patients have apparently normal heart pumping function, known as heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT07394010
- Testing
- Cardiopulmonary Exercise Test
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Ulster
Heart Failure With Preserved Ejection Fraction
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and…
- Trial name
- NCT04535726
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chongqing Medical University
Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III
PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
The PEP-HFpEF study is a prospective, single-center mechanistic study evaluating personalized heart rate pacing (myPACE) in patients with heart failure with preserved ejection fraction (HFpEF) and existing cardiac physiologic…
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association (NYHA) Class II
- Trial name
- NCT07864558
- Testing
- Individualized myPACE pacemaker programming
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Tufts Medical Center
Heart Failure With Preserved Ejection Fraction, Healthy
Understanding the Mechanisms of Diastolic Dysfunction
Heart failure is a clinical syndrome marked by breathlessness, even at low levels of exertion, general fatigue, and fluid retention and is estimated to affect 5.1 million people in the United States.
- Trial name
- NCT03340233
- Testing
- MRI (cardiac) off-label use gadolinium contrast (IND exempt), MRI (cardiac)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Heart Failure With Preserved Ejection Fraction
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
The clinical benefits of the dual Sodium-Glucose cotransporter (SGLT) 1 and 2-inhibition have recently been reported in two clinical trials.
- Trial name
- NCT05562063
- Testing
- Sotagliflozin
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Juan Badimon
Heart Failure
Chronotropic Incompetence in Patients With HFpEF
The purpose of this study is to determine the mechanisms of chronotropic incompetence (inability to increase heart rate with exercise) in patients with heart failure and preserved ejection fraction (HFpEF).
- Trial name
- NCT02524145
- Testing
- Static Handgrip, Dexmedetomidine, Glycopyrrolate
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure With Preserved Ejection Fraction
Risk Factors In Heart Failure Patients With Preserved Ejection Fraction
This study aimed to identify the independent risk factors associated with heart failure readmission, cardiac mortality and all-cause death among patients discharged from Xiangtan Central Hospital with heart failure and preserved…
- Trial name
- RIPE-HF (NCT06487468)
- Volunteers
- 9,419 people
- Sponsor
- Xiangtan Central Hospital
Type 2 Diabetes, Diabetic Cardiomyopathies
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
- Conditions
- Type 2 Diabetes, Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT04826159
- Testing
- IMB-1018972
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Imbria Pharmaceuticals, Inc.
Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes
Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart cannot fill with blood effectively. As a result, people with HFpEF suffer fatigue, breathlessness, and develop swollen limbs.
- Trial name
- MEMRI in HFpEF (NCT06652763)
- Testing
- Minnesota Living with Heart Failure Questionnaire, Echocardiogram, Six-minute walk test
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Leicester